Slide 1: Result presentation Q1/2022
5 May 2022, Seppo Kopsala, CEO / Lars Lindqvist, CFO Result presentation Q1/2022
Slide 2: Highlights
Highlights OPT@MED
Slide 3: Highlights Q1 2022
Q1 2022 Revenue decreased by 18.5% to EUR 3,214 (3,944) and gross margin 1. increased to 68.1% from 65.3% Highlights Q1 2022 The devices revenue from China declined over 90% - the rest of the 2. world grew over 50% 3. Aurora-AEYE process going forward as planned
Slide 4: Focus areas
Focus areas USA: • Another strong quarter in the US • Significant growth expectations • FDA clearance process remains our main strategic goal for the year China: • Previously, Phoebus’ exclusivity terminated & new national guidelines published recommending made-in-China fundus cameras • Covid-19 sit
Slide 5: Clinical Trial
Clinical Trial • 91.9% sensitivity • 93.6% specificity • 99+% imageability • Only a single image per eye Optomed and AEYE Health are seeking FDA clearance for the solution CAUTION - Investigational device. Limited by United States law to investigational use.
Slide 6: New US Business Model – Subscription
New US Business Model – Subscription Complete Solution Business Model Customer Benefits From product sales to complete screening solutions with diagnosis Solution leased, not No initial investments sold Only monthly rental fee Excellent clinical results, Fixed annual 91.9% sensitivity, subscription
Slide 7: Q1/2022 Financial highlights (KEUR)
Q1/2022 Financial highlights (KEUR) Q1/2022 Q1/2021 Change Revenue 3,214 3,944 -18.5% Gross profit 1) 2,190 2,577 -15.0% Gross margin 2) 68.1% 65.3% 280 bps Adjusted EBITDA -937 -315 -197.9% Adjusted EBITDA margin -29.2% -8.0% -2120 bps Net profit/ loss -1,370 -616 -122.5% Earnings per share -0.10 -
Slide 8: Devices segment highlights
Devices segment highlights OPT@MED
Slide 9: Devices segment highlights
Q1/2022 Q1/2021 Change Revenue from China decreased over 1. 90% - The weakened Covid-19 Devices segment highlights situation significantly hindering Revenue 1,065 1,447 -26.5% rebuilding Gross profit 641 842 -23.9% Other markets continued strong 2. with over 50% growth Gross margin 60.2% 58.2% 200 b
Slide 10: Software segment highlights
Software segment highlights
Slide 11: Software segment highlights
Q1/2022 Q1/2021 Change Revenue decreased as no large Software segment highlights software delivery projects were Revenue 2,150 2,497 -13.9% 1. completed during the quarter Gross profit 1,549 1,734 -10.7% The decline was partly Gross margin 72.0% 69.5% -250 bps compensated by the continued 2. stable
Slide 12: Outlook 2022
Outlook 2022 Optomed expects its full year 2022 revenue to grow compared to 2021 (Announced 17 February 2022)
Slide 13: Balance sheet
Balance sheet 31/03 2022 31/03 2021 Balance sheet ASSETS Goodwill 4,256 4,256 Development costs 6,623 5,842 • Equity ratio of 57.9 (64.2) percent Other intangible assets 2,299 2,718 Total intangible assets 13,177 12,816 • Total borrowings of EUR 6.5 (6.3) Total tangible assets 1,781 1,501 million To
Slide 14: Cash flow
Q1 2022 Q1 2021 Loss for the financial period -1,370 -616 Cash flow Cash flows before change in net working capital -893 2 Change in net working capital 239 -222 Cash flows before finance items -654 -221 • Cash flow from operating activities Cash flows from finance items -34 -36 amounted to EUR -0.7
Slide 15: Optomed's mission is to prevent blindness by improving access to eye screening globally
“ Optomed’s mission is to prevent blindness by improving access to eye screening globally Expansion into new Opening new customer Bringing AI-integrated geographical markets segments: primary care health screening to the market